• Ebru Sen, Tolga Canbak, Ozgur Bostanci, and Muharrem Battal.
• Department of General Surgery, Faculty of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkiye.
• J Coll Physicians Surg Pak. 2024 May 1; 34 (5): 604609604-609.

ObjectiveTo determine the associated risk factors for isolated liver metastasis in breast cancer patients and to detect the prognostic factors related to survival.Study DesignAnalytical study. Place and Duration of the Study: Department of General Surgery, The University of Health Sciences, Istanbul, Turkiye, from January 2011 to November 2020.MethodologyPatients with breast cancer liver metastasis who experienced surgery were retrospectively analysed for breast cancer and metastases-related characteristics. Descriptive statistical methods were used in the evaluation of data. Survival analyses were estimated by the Kaplan-Meier method. Log-rank and univariable Cox regression tests were utilised to search for prognostic factors' impact on survival.ResultsOut of 12 patients, 11 had recurrent disease after a median of 36 months of disease-free survival (DFS) and one patient had de novo metastasis. Grade 3 tumours and increased expression of Ki-67 had a negative effect on DFS. The median follow-up period was 66 months. Survival analysis showed 2- and 3-year progression-free survival (PFS); overall survival rates were 82%, 69%, 92%, and 82%, respectively. Development of liver metastasis in 3 years following breast cancer treatment was linked to worse PFS (p = 0.040).Conclusion Long-term survival is possible for breast cancer survivors with liver metastasis. Disease-free interval is an important determinant. Longer progression-free survival was detected in patients who had developed metastasis after three years of breast cancer treatment.Key WordsBreast cancer, Liver metastasis, Hepatic surgery.

18 keywords...

hide…